Flupentixol/melitracen
| Combination of | |
|---|---|
| Flupentixol | Typical antipsychotic |
| Melitracen | Tricyclic antidepressant |
| Clinical data | |
| Routes of administration | Oral |
| ATC code | N06CA02 (WHO) |
| Legal status | |
| Legal status |
|
| Identifiers | |
| (verify) | |
Flupentixol/melitracen (trade name Deanxit, Placida, Franxit, Anxidreg) is a combination of two psychoactive agents which has antidepressant properties. It is designed for short term usage only. It is produced by Lundbeck.[1]
Flupentixol/melitracen were banned in India by the country's Ministry of Health and Family Welfare on July 11, 2014,[2] and Lundbeck plans to take legal action to have the ban lifted.[3]
Other Brand names
Brand names include:
- Frenxit (Beximco Pharmaceuticals Ltd.)
- Sensit (Eskayef Bangladesh Ltd.)
- Renxit (Renata Ltd.)
- Melixol (Square Pharmaceuticals Ltd.)
- Melanxit (Organic Health Care Ltd.)
- Benzit (Bio-Pharma Ltd.)
- Leanxit (ACME Laboratories Ltd.)
See also
References
- ↑ Sweetman, Sean C., ed. (2009). "Preparations". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2607. ISBN 978-0-85369-840-1.
- ↑ "Ministry of Health and Family Welfare (Department of Health and Family Welfare) Notification, New Delhi" (PDF). The Gazette of India. July 11, 2014. Retrieved March 19, 2015 – via drugscontrol.org.
- ↑ Soma Das, ET Bureau (July 25, 2014). "Lundbeck to seek legal recourse after health ministry bans Deanxit again". Economic Times. Retrieved March 19, 2015.
This article is issued from Wikipedia - version of the 11/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.